Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385939 | 1.00 | MEN1 (0.47) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL30165334 | 0.88 | MEN1 (0.57) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL10992341 | 0.81 | MAOB (0.49) | NPC1RAB9ATSHRMAP4K4NFKB1 | |
| SCHEMBL10985177 | 0.78 | RAB9A (0.46) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL11630165 | 0.78 | MAOB (0.46) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL3152568 | 0.76 | KDM4E (0.42) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL30402035 | 0.76 | RAB9A (0.50) | MEN1ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL240423 | 0.76 | RAB9A (0.50) | MEN1ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL12101270 | 0.75 | ALDH1A1 (0.45) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL1133807 | 0.74 | IDO1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076259-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| US-4892873-A | MUSCLE RELAXANTS, ANTIEPILEPTIC, AN XIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4767765-A | ANXIOLYTIC OR ANTIEPILEPTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0223974-A1 | N-Substituted-N-[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-phenyl]alkanamides, carbamates and ureas | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
| US-4654343-A | USEFUL AS ANXIOLYTIC OR ANTIEPILEPTIC AGENTS AS WELL AS SEDATIVE-HYPNOTIC AND SKELETAL MUSCLE RELAXANT AGENTS | AMERICAN CYANAMID COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, HGFAC | MEN1 82/4885ALDH1A1 415/4885MAPT 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.